← Back to guidelines
Hematology7 papers

Epstein-Barr virus hepatitis

Last edited: 4/10/2026

Overview

Epstein-Barr virus (EBV) is a common herpesvirus that infects over 90% of the adult population globally 2. While often asymptomatic or causing mononucleosis, EBV is established as a significant factor in the development of several malignancies 2.

Diagnosis

No information on diagnosis is available in the provided abstracts.

Management

No information on management is available in the provided abstracts.

Special Populations

No information on special populations is available in the provided abstracts.

Key Recommendations

  • EBV is associated with a spectrum of cancers including nasopharyngeal carcinoma, gastric carcinoma, Hodgkin lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma, and extranodal NK/T-cell lymphoma, nasal type 2.
  • Advances in understanding EBV-related malignancies are ongoing, with studies analyzing their global epidemiology and geographic distribution 2.
  • The 9th European Conference on Infections in Leukaemia (ECIL-9) updated recommendations for viral hepatitis management in hematological malignancies and stem cell transplant recipients, focusing on HBV, HCV, and HEV 1.
  • References

    1 Mikulska M, van Bömmel F, Mouliade C, Indolfi G, Kefalakes H, von Lilienfeld-Toal M et al.. Updated recommendations for the management of hepatitis B, C, and E virus infections in patients with haematological malignancies and those undergoing haematopoietic cell transplantation: recommendations from the 9th European Conference on Infections in Leukaemia (ECIL-9). The Lancet. Haematology 2025. link00049-3) 2 Wong Y, Meehan MT, Burrows SR, Doolan DL, Miles JJ. Estimating the global burden of Epstein-Barr virus-related cancers. Journal of cancer research and clinical oncology 2022. link

    Original source

    1. [1]
    2. [2]
      Estimating the global burden of Epstein-Barr virus-related cancers.Wong Y, Meehan MT, Burrows SR, Doolan DL, Miles JJ Journal of cancer research and clinical oncology (2022)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG